COVA Study: Great Progress in the Samples Collection

More than 50% of targeted samples have been collected from healthy adolescents aged 11 years or above recruited with their parents in the COVID-19 Vaccination in Adolescents study.


At the moment, the families are offered to receive the BioNTech/Fosun BNT162b2 or SinoVac's CoronaVac. Each family can freely choose the vaccine they receive, given each family member receives the same vaccine.

Participants will report adverse reactions and other adverse events following immunization, and be followed up for immunogenicity assessments and vaccine breakthrough COVID-19 over a period of 3 years. Participants are covered by the Hong Kong government’s COVID-19 vaccine indemnity fund.

More about the COVA Study and conditions.

Many thanks to all participants and our very dedicated staff, working tirelessly for the success of this project!





  • LinkedIn
  • Facebook
  • Instagram
  • Twitter